Robert Van Sciver

Mr. Robert Van Sciver

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Clinical Biochemistry
Verified
Journal Article
Closed access
JGJohn J. Gildea
John J. Gildea
JSJoscelyn E. Seaton
Joscelyn E. Seaton
KVKen G. Victor
Ken G. Victor
CRCamellia M. Reyes
Camellia M. Reyes
DWDora Bigler Wang
Dora Bigler Wang
Robin A. FelderRobin A. Felder
Robin A. Felder

9 February 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SHSamantha P. Harris
Samantha P. Harris
BBBetty Belknap
Betty Belknap
RSRobert Van Sciver
Robert Van Sciver
HWHoward D. White
Howard D. White
VGVitold E. Galkin
Vitold E. Galkin
Mutations in genes encoding myosin, the molecular motor that powers cardiac muscle contraction, and its accessory protein, cardiac myosin binding protein C (cMyBP-C), are the two most common causes of hypertrophic cardiomyopathy (HCM). Recent studies established that the N-terminal domains (NTDs) of cMyBP-C (e.g., C0, C1, M, and C2) can bind to and activate or inhibit the thin filament (TF). However, the molecular mechanism(s) by which NTDs modulate interaction of myosin with the TF remains unknown and the contribution of each individual NTD to TF activation/inhibition is unclear. Here we used an integrated structure–function approach using cryoelectron microscopy, biochemical kinetics, and force measurements to reveal how the first two Ig-like domains of cMyPB-C (C0 and C1) interact with the TF. Results demonstrate that despite being structural homologs, C0 and C1 exhibit different patterns of binding on the surface of F-actin. Importantly, C1 but not C0 binds in a position to activate the TF by shifting tropomyosin (Tm) to the “open” structural state. We further show that C1 directly interacts with Tm and traps Tm in the open position on the surface of F-actin. Both C0 and C1 compete with myosin subfragment 1 for binding to F-actin and effectively inhibit actomyosin interactions when present at high ratios of NTDs to F-actin. Finally, we show that in contracting sarcomeres, the activating effect of C1 is apparent only once low levels of Ca2+ have been achieved. We suggest that Ca2+ modulates the interaction of cMyBP-C with the TF in the sarcomere.

1 August 2012 in Hypertension
Verified
Journal Article
Closed access
PDF file
JGJohn J. Gildea
John J. Gildea
XWXiaoli Wang
Xiaoli Wang
NSNeema Shah
Neema Shah
HTHanh Tran
Hanh Tran
MSMichael Spinosa
Michael Spinosa
RFRobin A. Felder
Robin A. Felder
Little is known regarding how the kidney shifts from a sodium and water reclaiming state (antinatriuresis) to a state where sodium and water are eliminated (natriuresis). In human renal proximal tubule cells, sodium reabsorption is decreased by the dopamine D 1 -like receptors (D 1 R/D 5 R) and the angiotensin type 2 receptor (AT 2 R), whereas the angiotensin type 1 receptor increases sodium reabsorption. Aberrant control of these opposing systems is thought to lead to sodium retention and, subsequently, hypertension. We show that D 1 R/D 5 R stimulation increased plasma membrane AT 2 R 4-fold via a D 1 R-mediated, cAMP-coupled, and protein phosphatase 2A–dependent specific signaling pathway. D 1 R/D 5 R stimulation also reduced the ability of angiotensin II to stimulate phospho-extracellular signal–regulated kinase, an effect that was partially reversed by an AT 2 R antagonist. Fenoldopam did not increase AT 2 R recruitment in renal proximal tubule cells with D 1 Rs uncoupled from adenylyl cyclase, suggesting a role of cAMP in mediating these events. D 1 Rs and AT 2 Rs heterodimerized and cooperatively increased cAMP and cGMP production, protein phosphatase 2A activation, sodium-potassium-ATPase internalization, and sodium transport inhibition. These studies shed new light on the regulation of renal sodium transport by the dopaminergic and angiotensin systems and potential new therapeutic targets for selectively treating hypertension.

16 September 2012
Verified
Book Chapter
Closed access
PDF file
JGJohn J. Gildea
John J. Gildea
HMHelen E. McGrath
Helen E. McGrath
RSRobert Van Sciver
Robert Van Sciver
DWDora Bigler Wang
Dora Bigler Wang
Robin A. FelderRobin A. Felder
Robin A. Felder

1 July 2014 in Kidney International
Verified
Journal Article
Open access
PDF file
JGJohn J. Gildea
John J. Gildea
ISIshan T. Shah
Ishan T. Shah
RSRobert Van Sciver
Robert Van Sciver
JIJonathan A. Israel
Jonathan A. Israel
CEChristoph Enzensperger
Christoph Enzensperger
Robin A. FelderRobin A. Felder
Robin A. Felder
Determining the individual roles of the two dopamine D1-like receptors (D1R and D5R) on sodium transport in the human renal proximal tubule has been complicated by their structural and functional similarity. Here we used a novel D5R-selective antagonist (LE-PM436) and D1R- or D5R-specific gene silencing to determine second messenger coupling pathways and heterologous receptor interaction between the two receptors. D1R and D5R colocalize in renal proximal tubule cells and physically interact, as determined by co-immunoprecipitation and fluorescent resonance energy transfer microscopy. Stimulation of renal proximal tubule cells with fenoldopam (D1R/D5R agonist) led to both adenylyl cyclase and phospholipase C (PLC) activation using real-time fluorescent resonance energy transfer biosensors ICUE3 and CYPHR, respectively. Fenoldopam increased cAMP accumulation and PLC activity and inhibited both NHE3 and NaKATPase activities. LE-PM436 and D5R siRNA blocked the fenoldopam-stimulated PLC pathway but not cAMP accumulation, whereas D1R siRNA blocked both fenoldopam-stimulated cAMP accumulation and PLC signaling. Either D1R or D5R siRNA, or LE-PM436 blocked the fenoldopam-dependent inhibition of sodium transport. Further studies using the cAMP-selective D1R/D5R agonist SKF83822 and PLC-selective D1R/D5R agonist SKF83959 confirmed the cooperative influence of the two pathways on sodium transport. Thus, D1R and D5R interact in the inhibition of NHE3 and NaKATPase activity, the D1R primarily by cAMP, whereas the D1R/D5R heteromer modulates the D1R effect through a PLC pathway.

1 March 2017 in Journal of Molecular Biology
Verified
Journal Article
Closed access
SJSilvana Jananji
Silvana Jananji
CRCristina Risi
Cristina Risi
ILIndeewari K.S. Lindamulage
Indeewari K.S. Lindamulage
LPLouis-Philippe Picard
Louis-Philippe Picard
RSRobert Van Sciver
Robert Van Sciver
VGVitold E. Galkin
Vitold E. Galkin